Tim Henkel

1.8k total citations · 1 hit paper
29 papers, 1.4k citations indexed

About

Tim Henkel is a scholar working on Epidemiology, Pharmacology and Infectious Diseases. According to data from OpenAlex, Tim Henkel has authored 29 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 10 papers in Pharmacology and 8 papers in Infectious Diseases. Recurrent topics in Tim Henkel's work include Antibiotics Pharmacokinetics and Efficacy (9 papers), Antibiotic Resistance in Bacteria (8 papers) and Antifungal resistance and susceptibility (5 papers). Tim Henkel is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (9 papers), Antibiotic Resistance in Bacteria (8 papers) and Antifungal resistance and susceptibility (5 papers). Tim Henkel collaborates with scholars based in United States, Germany and United Kingdom. Tim Henkel's co-authors include Beth P. Goldstein, James A. Dowell, Elyse Seltzer, V L Braciale, Hend Hanna, Issam Raad, Arnold Lentnek, Rabih O. Darouiche, Ray Hachem and José A. Vázquez and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Tim Henkel

28 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cefepime–Taniborbactam in Complicated Urinary Tract Infection

2024 67 citations Leanne B. Gasink, Paul C. McGovern et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Henkel United States	15	784	506	316	230	223	29	1.4k
Kathleen A. Stellrecht United States	19	809 1.0×	559 1.1×	129 0.4×	164 0.7×	402 1.8×	37	1.5k
Lemonia Skoura Greece	17	282 0.4×	301 0.6×	97 0.3×	73 0.3×	89 0.4×	114	1.1k
Stephen D. Allen United States	20	471 0.6×	643 1.3×	203 0.6×	48 0.2×	218 1.0×	53	1.2k
F. Meunier–Carpentier Belgium	17	689 0.9×	583 1.2×	276 0.9×	32 0.1×	219 1.0×	31	1.3k
R. Doug Hardy United States	24	605 0.8×	1.2k 2.4×	98 0.3×	159 0.7×	245 1.1×	43	1.9k
Lucía Gómez Spain	13	216 0.3×	581 1.1×	170 0.5×	40 0.2×	110 0.5×	24	1.0k
Frank Bally Switzerland	9	949 1.2×	1.3k 2.5×	84 0.3×	61 0.3×	68 0.3×	25	1.7k
Kalen Jacobson United States	19	523 0.7×	980 1.9×	158 0.5×	82 0.4×	108 0.5×	24	1.5k
Maureen H. Diaz United States	23	255 0.3×	720 1.4×	124 0.4×	58 0.3×	61 0.3×	44	1.5k
Lisa Y. Armitige United States	17	676 0.9×	487 1.0×	57 0.2×	197 0.9×	71 0.3×	29	1.0k

Countries citing papers authored by Tim Henkel

Since Specialization

Citations

This map shows the geographic impact of Tim Henkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Henkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Henkel more than expected).

Fields of papers citing papers by Tim Henkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Henkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Henkel. The network helps show where Tim Henkel may publish in the future.

Co-authorship network of co-authors of Tim Henkel

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Henkel. A scholar is included among the top collaborators of Tim Henkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Henkel. Tim Henkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moeck, Greg, Leanne B. Gasink, Rodrigo E. Mendes, et al.. (2024). Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial Agents and Chemotherapy. 68(7). e0023624–e0023624. 10 indexed citations

Gasink, Leanne B., Paul C. McGovern, Greg Moeck, et al.. (2024). Cefepime–Taniborbactam in Complicated Urinary Tract Infection. New England Journal of Medicine. 390(7). 611–622. 67 indexed citations breakdown →

Dörr, Marcus, Leanne B. Gasink, Tim Henkel, et al.. (2023). 2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI). Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Moeck, Greg, Leanne B. Gasink, Marcus Dörr, et al.. (2023). 2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study. Open Forum Infectious Diseases. 10(Supplement_2). 2 indexed citations

Dowell, James A., Thomas Marbury, William B. Smith, & Tim Henkel. (2022). Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment. Antimicrobial Agents and Chemotherapy. 66(9). e0025322–e0025322. 25 indexed citations

Wechsler, Michael E., Patricia C. Fulkerson, Bruce S. Bochner, et al.. (2012). Novel targeted therapies for eosinophilic disorders. Journal of Allergy and Clinical Immunology. 130(3). 563–571. 77 indexed citations

Mathur, Sameer K., Mario Castro, Frederick E. Hargreave, et al.. (2011). Efficacy of Reslizumab in Patients with Poorly Controlled Eosinophilic Asthma: Subgroup Analysis of Patients with Nasal Polyps. Journal of Allergy and Clinical Immunology. 127(2). AB84–AB84. 3 indexed citations

Pfaller, Michael A., R. J. Hollis, Beth P. Goldstein, et al.. (2010). In Vitro Activity of Anidulafungin and Other Agents against Esophageal Candidiasis-Associated Isolates from a Phase 3 Clinical Trial. Journal of Clinical Microbiology. 48(7). 2613–2614. 2 indexed citations

Raad, Issam, Rabih O. Darouiche, José A. Vázquez, et al.. (2005). Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens. Clinical Infectious Diseases. 40(3). 374–380. 232 indexed citations

10.

Herbrecht, Raoul, Donald R. Graham, Mindy G. Schuster, et al.. (2004). Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericn B (LAmB) for the treatment of invasive aspergillosis (IA). Biology of Blood and Marrow Transplantation. 10. 91–91. 10 indexed citations

11.

Krause, David S., A. E. Simjee, C.E.J. Van Rensburg, et al.. (2004). A Randomized, Double-Blind Trial of Anidulafungin versus Fluconazole for the Treatment of Esophageal Candidiasis. Clinical Infectious Diseases. 39(6). 770–775. 169 indexed citations

12.

Dowell, James A., et al.. (2004). Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal. The Journal of Clinical Pharmacology. 44(6). 590–598. 142 indexed citations

13.

Dowell, James A., et al.. (2003). Dalbavancin pharmacokinetics in subjects with mild or moderate hepatic impairment. 43. 4. 1 indexed citations

14.

Dowell, Jonathan E., et al.. (2003). A clinical mass balance study of anidulafungin showing complete fecal elimination. 43. 32. 8 indexed citations

15.

Seltzer, Elyse, et al.. (2003). Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections. Clinical Infectious Diseases. 37(10). 1298–1303. 198 indexed citations

16.

Ball, Peter, Robert Wilson, Lionel A. Mandell, Joshua I. Brown, & Tim Henkel. (2001). Efficacy of Gemifloxacin in Acute Exacerbations of Chronic Bronchitis: a Randomised, Double-Blind Comparison with Trovafloxacin. Journal of Chemotherapy. 13(3). 288–298. 17 indexed citations

17.

Henkel, Tim, et al.. (1999). Emergence of Resistance during Mupirocin Treatment: is it a Problem in Clinical Practice?. Journal of Chemotherapy. 11(5). 331–337. 35 indexed citations

18.

Behlke, Mark A., Tim Henkel, Sarah Anderson, et al.. (1987). Expression of a murine polyclonal T cell receptor marker correlates with the use of specific members of the V beta 8 gene segment subfamily.. The Journal of Experimental Medicine. 165(1). 257–262. 70 indexed citations

19.

Braciale, Thomas J., V L Braciale, Tim Henkel, Joe Sambrook, & M J Gething. (1984). Cytotoxic T lymphocyte recognition of the influenza hemagglutinin gene product expressed by DNA-mediated gene transfer.. The Journal of Experimental Medicine. 159(2). 341–354. 72 indexed citations

20.

Kaplan, David R., Tim Henkel, V L Braciale, & T J Braciale. (1984). Mycoplasma infection of cell cultures: thymidine incorporation of culture supernatants as a screening test.. The Journal of Immunology. 132(1). 9–11. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact